Lintas, Estrella M.

HRN: 28-22-09  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/05/2026
CEFUROXIME 750MG (VIAL)
04/05/2026
04/12/2026
IV
1.5 LD Then 750mg
LD Then Q8
Cholelithiasis
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Intra-abdominal    Compliance to guidelines: